Search - tctmd.com

Displaying 241 - 260 of 504

Sort: Relevancy | Date

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

News Conference News AHA 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

November 05, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

Presentation Cardiovascular Interventions 2022

Do All Patients with New Onset HF Need Assessment for CAD?

Presenter: J. Thomas Heywood

October 28, 2022

STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF

News Daily News

STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF

October 17, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

October 04, 2022

October 2022 News Roundup

News Opinion CV Team Dispatch

October 2022 News Roundup

October 01, 2022

Most Patient-Reported Outcome Measures in CVD Fall Short

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

September 23, 2022

Moving Beyond Pharmacotherapy: The Transformative Role of Devices in HF Treatment

Presentation TCT 2022

Moving Beyond Pharmacotherapy: The Transformative Role of Devices in HF Treatment

Presenter: William Abraham

September 16, 2022

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

News Daily News

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

September 09, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

August 27, 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.